FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval
Article Related Press Releases (1) Related Articles (4) Related SEC Filings (1) Stock Quotes (1) Comments (0)
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Below is the FDA's approval letter Heron Therapeutics' (Nasdaq: HRTX) SUSTOL:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Heron Therapeutics (HRTX) Prices Offering at $12.20/Share
- Heron Therapeutics (HRTX) to Offer $150M in Common Stock
- Generics File Against New Teva Pharma (TEVA) Copaxone 40MG Patent - Evercore ISI
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!